Objective: to explore the effect of combined application of calcitonin and alendronate in the clinical treatment of osteoporosis. Methods: this article collected and selected 60 patients with osteoporosis who were adm...Objective: to explore the effect of combined application of calcitonin and alendronate in the clinical treatment of osteoporosis. Methods: this article collected and selected 60 patients with osteoporosis who were admitted to the department of orthopedics in our hospital from November 2020 to October 2021, and randomly divided the experimental patients into a control group (30 cases) and a research group (30 cases). The control group was treated with calcitonin drugs, and the study group was treated with a moderate amount of alendronate on the basis of the control group, and the changes in bone mineral density, biochemical indicators, incidence of adverse reactions, and incidence of adverse reactions were compared between the two groups before and after treatment. Clinical treatment effect. Results: after statistical study, there was no special difference in bone mineral density between the study group and the control group before treatment (P > 0.05). After treatment, the bone mineral density of femur (0.91 ± 0.05) and lumbar spine (0.97 ± 0.26) in the study group were higher than those in the control group (0.72 ± 0.08), (0.83 ± 0.24);The relevant biochemical indexes in the study group were better than those in the control group;The overall incidence of nausea, vomiting, constipation, fever and other adverse reactions in the study group was 13.3%, which had no special difference from 23.3% in the control group (P > 0.05);The clinical therapeutic effect of the study group was 96.7%, which was higher than 80.0% of the control group. The specific difference between the two groups was statistically significant (P < 0.05). Conclusion: in the clinical treatment of patients with osteoporosis, the combined use of calcitonin and alendronate has a very significant effect. These two drugs can alleviate the symptoms of patients, increase the overall bone density of patients, and promote their body-related biochemical indicators. Early recovery can improve the quality of daily life while maintaining their health and safety, which is worthy of clinical application and promotion.展开更多
文摘Objective: to explore the effect of combined application of calcitonin and alendronate in the clinical treatment of osteoporosis. Methods: this article collected and selected 60 patients with osteoporosis who were admitted to the department of orthopedics in our hospital from November 2020 to October 2021, and randomly divided the experimental patients into a control group (30 cases) and a research group (30 cases). The control group was treated with calcitonin drugs, and the study group was treated with a moderate amount of alendronate on the basis of the control group, and the changes in bone mineral density, biochemical indicators, incidence of adverse reactions, and incidence of adverse reactions were compared between the two groups before and after treatment. Clinical treatment effect. Results: after statistical study, there was no special difference in bone mineral density between the study group and the control group before treatment (P > 0.05). After treatment, the bone mineral density of femur (0.91 ± 0.05) and lumbar spine (0.97 ± 0.26) in the study group were higher than those in the control group (0.72 ± 0.08), (0.83 ± 0.24);The relevant biochemical indexes in the study group were better than those in the control group;The overall incidence of nausea, vomiting, constipation, fever and other adverse reactions in the study group was 13.3%, which had no special difference from 23.3% in the control group (P > 0.05);The clinical therapeutic effect of the study group was 96.7%, which was higher than 80.0% of the control group. The specific difference between the two groups was statistically significant (P < 0.05). Conclusion: in the clinical treatment of patients with osteoporosis, the combined use of calcitonin and alendronate has a very significant effect. These two drugs can alleviate the symptoms of patients, increase the overall bone density of patients, and promote their body-related biochemical indicators. Early recovery can improve the quality of daily life while maintaining their health and safety, which is worthy of clinical application and promotion.
